{'52WeekChange': 0.54999995,
 'SandP52WeekChange': None,
 'address1': '3655 Nobel Drive',
 'address2': 'Suite 260',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.25,
 'askSize': 900,
 'averageDailyVolume10Day': 1523387,
 'averageVolume': 926028,
 'averageVolume10days': 1523387,
 'beta': 1.465719,
 'beta3Year': None,
 'bid': 1.2,
 'bidSize': 2900,
 'bookValue': 0.13,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.25,
 'dayLow': 1.2,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.817,
 'enterpriseToRevenue': None,
 'enterpriseValue': 28149624,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.0844285,
 'fiftyTwoWeekHigh': 2.22,
 'fiftyTwoWeekLow': 0.69,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 23880849,
 'forwardEps': -0.56,
 'forwardPE': -2.1785715,
 'fromCurrency': None,
 'fullTimeEmployees': 15,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.12652001,
 'heldPercentInstitutions': 0.03721,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1500508800,
 'lastSplitFactor': '1:10',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/darebioscience.com',
 'longBusinessSummary': 'Dar√© Bioscience, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing and '
                        "marketing women's reproductive health products in the "
                        'United States. The company intends to develop '
                        'therapies in the areas of contraception, vaginal '
                        'health, sexual health, and fertility. Its product '
                        'portfolio includes Ovaprene, a non-hormonal monthly '
                        'contraceptive vaginal ring; Sildenafil Cream, a novel '
                        'cream formulation of sildenafil to treat female '
                        'sexual arousal disorder utilizing the active '
                        'ingredient in Viagra; DARE-BV1, a hydrogel '
                        'formulation of clindamycin phosphate 2% to treat '
                        'bacterial vaginosis via a single application; and '
                        'DARE-HRT1, a combination of bio-identical estradiol '
                        'and progesterone intravaginal ring for hormone '
                        'replacement therapy. The company has license '
                        'agreement with ADVA-Tec, Inc. to develop and '
                        'commercialize Ovaprene for human contraceptive use; '
                        'and license and collaboration agreement with '
                        'Strategic Science and Technologies-D, LLC and '
                        'Strategic Science Technologies, LLC to develop and '
                        'commercialize indications for women related to female '
                        'sexual dysfunction and/or female reproductive health. '
                        'The company is headquartered in San Diego, '
                        'California.',
 'longName': 'Dare Bioscience, Inc.',
 'market': 'us_market',
 'marketCap': 32508364,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_423979060',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -16253832,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.25,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858-926-7655',
 'previousClose': 1.24,
 'priceHint': 4,
 'priceToBook': 9.384616,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.25,
 'regularMarketDayLow': 1.2,
 'regularMarketOpen': 1.25,
 'regularMarketPreviousClose': 1.24,
 'regularMarketPrice': 1.25,
 'regularMarketVolume': 293051,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 26646200,
 'sharesPercentSharesOut': 0.0099,
 'sharesShort': 263105,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 200323,
 'shortName': 'Dare Bioscience, Inc.',
 'shortPercentOfFloat': 0.0105,
 'shortRatio': 0.6,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'DARE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.87,
 'twoHundredDayAverage': 1.0856115,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '79b82021-a19d-3c2b-be19-b7a9d44205d1',
 'volume': 293051,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.darebioscience.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92122'}